Clene
CLNN | NASDAQ
$3.75
-$0.17 (-4.34%)
At close: Nov 16, 2026, 3:59 PM ET
$3.65
-$0.10 (-2.67%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-4.34%
(1D)No price chart data available for 1D timeframe.
Rating
43.2
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #436/1021 (Top 43%)
Key Statistics
Market Data
Market Cap $54M
1D Range
3.55 3.84
52W Range
3.10 10.36
Valuation (TTM)
PE -1.42
PB -3.65
EV/EBITDA -2.56
Valuation (NTM)
Forward PE N/A
Forward PEG 0.11
Price Target $50.00
Cash Flow
FCF Yield -30.8%
SBC Adj. FCF Yield -42.8%
SBC Impact -39.1%
Margins
Gross Margin -80.7%
Operating Margin -8823.1%
FCF Margin -6986.9%
Growth (CAGR)
Revenue 3Y | 5Y -30.8% |
-15.5%
Dil EPS 3Y | 5Y 37.0% |
29.4%
FCF 3Y | 5Y 18.0% |
25.9%
Returns
ROA -121.1%
ROE 175.4%
ROIC -111.8%
Financial Health
Net Debt
$9.33M
Current Ratio 0.85
Interest Coverage -7.25
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nan...
Sector Healthcare
Industry Biotechnology
Employees 78
IPO Date Oct 18, 2018
Website clene.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 4, 2026
EPS
$0.05
Beat +111.01%
YoY:
+105.88% REV
$56K
Miss -20.00%
YoY:
+273.33%Next Earnings
Mar 11, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$50.00
Upside
+1233.33%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CLNN